CalciMedica (CALC) CEO Rachel Leheny Receives 186,729-Share Award

What Happened Rachel Leheny, CEO of CalciMedica, was granted two derivative awards on August 19, 2026, each for 186,729 shares, for a total of 373,458 shares. Each award is reported at $0.00 on the Form 4 and is listed as a derivative security (i.e., a warrant or similar right to acquire common stock), not immediate common-stock issuance.

Key Details

• Transaction date: August 19, 2026; Form 4 filed August 21, 2026 (appears timely — two business days after the transaction).
• Grants: Two derivative awards of 186,729 shares each; total 373,458 shares; reported acquisition price $0.00.
• Shares owned after transaction: Not specified in the provided filing data.
• Footnote F1: The securities were issued under a Securities Purchase Agreement dated June 23, 2026 (closing June 25, 2026) approved by an independent board committee.
• Footnotes F2 & F3: Describe exercise windows and limits:
  • One warrant: exercisable on/after Aug 19, 2026 until the earlier of Dec 25, 2027 or 30 days after FDA IND clearance for CM5480; exercise restricted if post-exercise beneficial ownership would exceed a cap (not to exceed 19.99%).
  • The other warrant: exercisable on/after Aug 19, 2026 until June 25, 2031, subject to the same beneficial-ownership cap (≤19.99%).
• Filing code: Transaction type reported as "A" (award/grant).

Context These are derivative awards (likely warrants) that give the right to acquire common stock in the future under specified exercise windows and ownership limits; they do not represent immediate shares outstanding. The grants were part of a previously negotiated Securities Purchase Agreement and were approved by an independent committee. No sale or cash exercise was reported here — this is an issuance of rights rather than a market purchase or immediate stock sale.